SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
II-VI Incorporated (IIVI) trades at a trailing P/E of 732.5. Trailing earnings yield is 0.14%.
Criteria proven by this page:
- VALUE (15/100, Fail) — trailing P/E is well above the S&P 500 average of ~25, suggesting a premium valuation (P/E 732.5); trailing earnings yield is below the 10-year Treasury yield (~4.3%), meaning bonds offer a better return (EY 0.14%).
- Trailing Earnings Yield 0.14% — below bond yields — investors are paying a premium for expected growth rather than current earnings.
Overall SharesGrow Score: 55/100 with 2/7 criteria passed.
SharesGrow 7-Criteria Score
✗
VALUE
15/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
100/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — IIVI
Valuation Multiples
P/E (TTM)732.5
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio6.25
EV/EBITDA0.0
Per Share Data
EPS (TTM)$0.31
Book Value / Share$0.00
Revenue / Share$36.31
FCF / Share$0.00
Yields & Fair Value
Earnings Yield0.14%
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$1.04 |
$827.22M |
$65.49M |
7.9% |
| 2017 |
$1.48 |
$972.05M |
$95.27M |
9.8% |
| 2018 |
$1.35 |
$1.16B |
$88M |
7.6% |
| 2019 |
$1.63 |
$1.36B |
$107.52M |
7.9% |
| 2020 |
$-0.79 |
$2.38B |
$-67.03M |
-2.8% |
| 2021 |
$2.37 |
$3.11B |
$297.55M |
9.6% |
| 2022 |
$1.45 |
$3.32B |
$234.76M |
7.1% |
| 2023 |
$-1.89 |
$5.16B |
$-259.46M |
-5% |
| 2024 |
$-1.84 |
$4.71B |
$-156.15M |
-3.3% |
| 2025 |
$0.31 |
$5.81B |
$49M |
0.8% |
